C Ray Therapeutics raises $100 million to develop radiopharmaceuticals
The financing round will fund the improvement of the company’s technology platform for the discovery and development of innovative radionuclide drug conjugates.
Bioavailbility challenge
Andelyn Biosciences selected to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome
Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been chosen by UMass Chan Medical School to manufacture clinical-grade AAV9-CSA vector using its suspension AAV Curator Platform to...
Breaking boundaries: 11 FemTech start-ups poised to transform women’s health
In a resounding declaration of commitment to women’s health, Discovery Park, Kent’s well-known life science and innovation community, has unveiled its latest cohort of trailblazing FemTech start-ups.
From a fascination with viruses to a desire to make a lasting impact, Immunic's Hella Kohlhof shares her journey
Wedneday is Women in Science day and we have a fantastic interview with Hella who is co-founder and chief scientific officer of Immunic Therapeutics.
Thermo Fisher's research business, PPD, to explore effective treatments for ARDS in large trial
There is an urgent and unmet need to better understand the features of acute respiratory distress syndrome (ARDS), which is why a clinical research business has been selected to start a phase 2 platform clinical trial to investigate it further.
Piramal Pharma has launched a high-throughput screening facility
Piramal Pharma has launched a high-throughput screening facility at its drug discovery services site in Ahmedabad, India.
The brave new world of enzyme replacement therapy: Revolutionising rare disease treatment using facilitated transcytosis
Enzyme replacement therapy (ERT) made its debut in 1991, heralding a breakthrough in medical science for individuals and families grappling with rare diseases stemming from single gene mutations.
M&G’s Catalyst invests $57 million with SkyCell to improve transportation of temperature-controlled medicines
M&G Investments has made a $57 million investment with Swiss-based tech firm, SkyCell and says it is seeking to change the face of international pharma supply chains.
Depression and anxiety oral drug patented in Europe by Vistagen
A stand alone drug for people living with depression and anxiety has been patented by biopharmaceutical company, Vistagen.
Live biotherapeutic complements antibiotics in serious hospital infection
A live biotherapeutics product used alongside antibiotics can help combat C. difficile infection (CDI).
Pharmanovia taps Nanoform to improve bioavailability of ‘iconic branded medicine’
The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.
TFF completes enrollment in early-phase trial of inhaled COVID-19 therapy
The pharmaceutical company, which uses thin-film freezing to develop inhalable therapies, has completed enrollment in the first phase for its drug candidate.
TFF completes dosing in Phase Ib clinical study for asthma drug
The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
CPHI WORLDWIDE
Carrier solution addresses challenging liquid APIs: W.R. Grace
The CPhI Worldwide exhibitor will show Syloid XDP, a silica carrier designed to convert liquid, waxy, or oily active ingredients into free-flowing powders.
From the show floor: Exhibitors at CPhI Worldwide 2021
CPhI Worldwide welcomes attendees back to the show floor in person this month. We put the spotlight on some of the exhibitors who will be there.
Inflammasome develops combo HIV/birth control implant
Thanks in part to grants from the Gates Foundation, the company has come up with a bioerodible implant that combines HIV prevention and birth control.
Hot-melt extrusion can improve bioavailability: Avomeen
With bioavailability challenges a frequent frustration for drug developers, one research outfit suggests a technique that could reduce the headaches.
Online HPAPI Summit takes on key pharma ingredients topics
The virtual event (scheduled June 22-24) will feature presentations from Bayer, Merck, GSK, Novartis, Takeda, FDA, WHO, and other notable organizations.
Lonza leader outlines small-molecule trends for 2021 and beyond
The head of small-molecule business for the pharma solutions specialist talks about obstacles, and how companies can work to clear them for future success.
Lonza expands solid-form services at Oregon facility
The company has increased capabilities at its Bend, Oregon location, including its SimpliFiH Solutions first-in-human services for small-molecule drugs.
Lexaria broadens COVID-19 drug exploration program
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
Sandoz incorporates RFID technology on injectables
The generic drug manufacturer is working with Kit Check to incorporate the company's drug supply-chain management technology into two of its products.
CPhI Festival of Pharma
CPhI: Dramatic changes ahead for the generics market
Technology impacting generic drugs include artificial intelligence, telemedicine, fraud-preventing digital solutions and more, according to a report
TFF, Union Therapeutics join on potential COVID-19 treatment
The companies will partner on developing dry-powder forms of niclosamide as a treatment for the virus, using thin-film freezing technology.
Webinar delves into drug delivery innovations
Innovations in Drug Delivery Part II, a free online event on July 15, will feature novel technologies and innovative solutions to current challenges.
Takeda taps Evox for exosome therapeutics
The partners will focus on developing five potential exosome treatment for rare diseases.
Formulation method improves bioavailability of poorly soluble molecules
Orion to benefit from Nanoform’s formulation technology, which is able to improve bioavailability and solubility of early-stage compounds.
FDA approves biodegradable implant for eye conditions
Allergan’s intracameral sustained-release implant receives US FDA approval for two indications treating ophthalmic conditions.
Merck KGaA partners on 3D-printed tablets manufacture
Merck to produce 3D-printed tablets by tapping into the technology developed by AMCM, making a move towards digitalization.
Formulation technology improving CBD uptake bought out
Bioavailability of water insoluble compounds, such as CBD, enhanced up to 15 times with the technology of Solmic, leading to its acquisition by Betterlife.
Patient confidence key in switching delivery of biosimilars
As developers of biosimilars look at ways of differentiating from originator products, experts warn that patients will need to be brought on board.
RaniPill passes Phase I test for orally delivered biologics
Rani Therapeutics releases positive results from a Phase I clinical study into delivering octreotide by RaniPill.
Partnership aims to identify over 8,000 antibiotic-resistant pathogens
Noscendo builds on its diagnostic platform to enable identification of antibiotic resistant microorganisms, in partnership with German hospital.
Prices of nearly 500 drugs increased in 2020
Nearly 500 prescription drugs will become more costly in 2020, as drugmakers proceed with prices increases averaging 5%, 3 Axis Advisors says.
Asahi Kasei in $1.3bn bid to access US pharma market
Asahi Kasei has a bid accepted for oral dose specialist, Veloxis, with one eye on gaining a position in the US market.
Zosano readies contract manufacturers for pre-approval inspections
Zosano Pharma prepares contract manufacturers to host pre-approval inspections to support filing for approval of migraine drug.
FDA report on drug shortages recommends rating system for manufacturers
FDA urges manufacturers to ‘sell quality’ to fight drug shortages, releasing a report on the potential introduction of a rating system to reward transparency and investments in quality management.
GSK develops new chemical-class antibiotic to fight AMR
GSK announces it initiated Phase III trials for gepotidacin, the first in a new class of antibiotics, as an potential treatment for urinary tract infection.
Bryn declares patient preference for nasal spray over EpiPen
Bryn Pharma presents data from a patient study that showed a consistent choice of its nasal spray formulation of epinephrine over Mylan’s EpiPen.
Foamix enters commercial supply agreement for topical foam antibiotic
Foamix signs deal with ASM for the commercial manufacture and supply of recently approved Amzeeq and its lead candidate, FMX103.
Tricking bacteria into opening pores for effective drug delivery
Research has discovered that bacteria will open holes in their cell wall under certain conditions, potentially leading to a new drug target or greater potency of existing antibiotics.
AbbVie’s HCV treatment receives first for shorter treatment cycle
US FDA granted expanded approval for Mavyret that will allow patients to be treated for the hepatitis C virus in eight weeks.
Novo Nordisk gets nod for oral diabetes drug
US FDA provides the first ever approval of an oral GLP-1 treatment to Novo Nordisk, for the treatment of type 2 diabetes.
Future of diabetes care will be about data
Insulin dosing and glucose level monitoring data combined in one platform is the object of two major partnerships focusing on diabetes.
Mundipharma bets $568m on antifungal treatment
Mundipharma signs agreement to progress an antifungal candidate through to commercialization, with the potential for it to become the first approved treatment in 13 years.
Licensing agreement formalizes drug delivery technology partnership
Enteris enters a licensing agreement with Cara Therapeutics for the ongoing development of the latter’s drug candidate as it continues clinical trials.
Scorpion venom provides clues for chronic pain and drug delivery
Researchers discover scorpion toxin that triggers pain through a previously unknown pathway, potentially opening up new avenues of investigation for treating chronic pain.
GSK releases positive data on long-acting HIV treatment
GSK announces that its injectable HIV treatment was able to suppress the virus when administered every two months.
Roche’s tumour-agnostic drug approved by FDA, priced under competitor drug
Roche receives US FDA approval with two indications for Rozlytrek, prices the drug at almost half of Bayer’s similar drug.
AI platform identifies anti-cancer uses in non-cancer generics
'Oncology Repurposing Engine' uses artificial intelligence to identify potential drug candidates among generics and off-patent drugs that may be repurposed as cancer therapies.